

Program

TUESDAY, JUNE 26, 2018

15:00–17:00 Registration

17:10–17:15 Opening Remarks: Kouji MATSUSHIMA

17:15–18:05 Plenary Lecture 1

Chair: Kouji MATSUSHIMA

T Cell Exhaustion and PD-1 Directed Immunotherapy24

Rafi AHMED

(School of Medicine, Emory University, Rollins Research Center, USA)

18:05–18:55 Plenary Lecture 2

Chair: Hiroyoshi NISHIKAWA

Immunologic Checkpoint Blockade: Exploring Combinations and Mechanisms
.....26

Jedd D. WOLCHOK

(Memorial Sloan Kettering Cancer Center, USA)

18:55–20:30 Welcome Reception

WEDNESDAY, JUNE 27, 2018

9:00–12:20 Session A

Immunological Bases I

Chairs: Hiroyoshi NISHIKAWA

Ira MELLMAN

9:00–9:40 [A-1] The mechanistic basis of cancer immunotherapy28

Ira MELLMAN

(Cancer Immunology, Genentech, USA)

9:40–10:10 [A-2] The role of SASP and anti-tumor immunity in tumor microenvironment of obesity-associated liver cancer30

Naoko OHTANI

(Department of Pathophysiology, Graduate School of Medicine,
Osaka City University, Japan)

10:10–10:40 Coffee Break

- 10:40–11:10 [A-3]**
A novel pathogenic role of IL-34 in cancer32
Ken-ichiro SEINO
 (Division of Immunobiology, Institute for Genetic Medicine,
 Hokkaido University, Japan)
- 11:10–11:50 [A-4]**
Cross-presenting dendritic cell within the tumor microenvironment
34
Stefani SPRANGER
 (David H. Koch Institute for Integrative Cancer Research at
 Massachusetts Institute of Technology, USA)
- 11:50–12:20 [A-5]**
Immuno-genome analyses to decipher anti-tumor immune responses
36
Hiroyoshi NISHIKAWA
 (Division of Cancer Immunology, Research Institute/EPOC,
 National Cancer Center, Japan/
 Department of Immunology, Nagoya University
 Graduate School of Medicine, Japan)
- 12:20–14:30 Lunch**
- 14:30–18:35 Session B**
Immunological Bases II
 Chairs: Yutaka KAWAKAMI
 E. John WHERRY
- 14:30–15:00 [B-1]**
Therapeutic vaccine immunotherapy for cancer without cytokine toxicity38
Tsukasa SEYA
 (Department of Vaccine Immunology, Graduate School of Medicine,
 Hokkaido University, Japan)
- 15:00–15:40 [B-2]**
Type II NKT cell-induced immunoregulatory pathway as a potential target for immunotherapy40
Masaki TERABE
 (Vaccine Branch, National Cancer Institute, NIH, USA)
- 15:40–16:20 [B-3]**
Molecular Basis of T Cell Exhaustion: Insights for immunotherapy
42
E. John WHERRY
 (Department of Microbiology, University of Pennsylvania, USA)
- 16:20–16:50 Coffee Break**
- 16:50–17:20 [B-4]**
Immunological Subtypes of Human Cancers and their Modulations for Combination Immunotherapy44
Yutaka KAWAKAMI
 (Institute for Advanced Medical Research,
 Keio University School of Medicine, Japan)

- 17:20–17:50 [B-5]**
Novel technologies in CAR-T cells for the treatment of solid tumors46
Koji TAMADA
 (Department of Immunology, Yamaguchi University
 Graduate School of Medicine, Japan)
- 17:50–18:05 [Short Talk 1 (PS[I]-05)]**
Phosphoinositide-3-kinase-delta as a regulator of regulatory T cell suppressive function89
Ee Lyn LIM
 (Immunology Frontier Research Center, Osaka University, Japan)
- 18:05–18:20 [Short Talk 2 (PS[I]-13)]**
Immunosuppressive effects of IL-6/sIL-6R on Th1-cell-mediated anti-tumor immunity in tumor-bearing hosts98
Yasuharu NISHIMURA
 (Institute of Resource Development and Analysis,
 Kumamoto University, Japan/
 Department of Immunogenetics,
 Graduate School of Medical Sciences,
 Kumamoto University, Japan)
- 18:20–18:35 [Short Talk 3 (PS[I]-25)]**
Targeting the Hippo intracellular signaling pathway for cancer immunotherapy111
Toshiro MOROISHI
 (Department of Molecular Enzymology, Faculty of Life Sciences,
 Kumamoto University, Japan)

18:35–19:30 Dinner

19:30–20:30 Poster Discussion I (Odd Numbers)

20:30–21:30 Poster Session

THURSDAY, JUNE 28, 2018

- 9:00–12:20 Session C**
Immune and Cancer Metabolism
 Chairs: Heiichiro UDONO
 Greg M. DELGOFFE
- 9:00–9:40 [C-1]**
Tumor microenvironment metabolism as a primordial checkpoint on antitumor immunity48
Greg M. DELGOFFE
 (Immunology, University of Pittsburgh, USA)
- 9:40–10:10 [C-2]**
NRF2 addiction in cancer cells and its impact on metabolism50
Hozumi MOTOHASHI
 (Institute of Development, Aging and Cancer, Tohoku University, Japan)

- 10:10–10:40 [C-3]**
Modulation of fatty acid oxidation in T cells improves the PD-1 blockade therapy52
Kenji CHAMOTO
 (Department of Immunology and Genomic Medicine,
 Kyoto University Graduate School of Medicine, Japan)
- 10:40–11:10 Coffee Break**
- 11:10–11:50 [C-4]**
Lipid metabolism and T-cell immunity54
Chenqi XU
 (State Key Laboratory of Molecular Biology, Institute of Biochemistry
 and Cell Biology, Chinese Academy of Sciences, China)
- 11:50–12:20 [C-5]**
Metformin drives metabolic reprogramming of tumor microenvironment, leading to inhibition of tumor growth56
Heiichiro UDONO
 (Department of Immunology, Okayama University
 Graduate School of Medicine,
 Dentistry and Pharmaceutical Sciences, Japan)
- 12:20–14:30 Lunch**
- 14:30–18:35 Session D**
New Technologies in Cancer Research
 Chairs: Kazuhiro KAKIMI
 Zlatko TRAJANOSKI
- 14:30–15:10 [D-1]**
CRISPR-Cas9 genetic screens to improve adoptive cancer immunotherapies58
Shashank J. PATEL
 (Department of Cancer Immunology and Immune Modulation,
 Boehringer Ingelheim, USA)
- 15:10–15:50 [D-2]**
Computing and probing cancer immunity60
Zlatko TRAJANOSKI
 (Division of Bioinformatics, Medical University of Innsbruck, Austria)
- 15:50–16:20 [D-3]**
An immunogram for the cancer-immunity cycle62
Kazuhiro KAKIMI
 (Department of Immunotherapeutics,
 The University of Tokyo Hospital, Japan)
- 16:20–16:50 Coffee Break**

-
- 16:50–17:20 [D-4]**
Landscape of natural HLA class I ligand peptides of cancer cells
66
Toshihiko TORIGOE
 (Department of Pathology 1, Sapporo Medical University
 School of Medicine, Japan)
- 17:20–17:50 [D-5]**
Single-cell gene expression profiling of the tumor microenvironment
68
Shinichi HASHIMOTO
 (Department of Integrative Medicine for Longevity,
 Graduate School of Medical Sciences,
 Kanazawa University, Japan)
- 17:50–18:05 [Short Talk 4 (PS[II]-24)]**
Metabolic Reprogramming requires Stem Cell Memory T Cells phenotypes for Adoptive Immunotherapy110
Taisuke KONDO
 (Department of Microbiology and Immunology,
 Keio University School of Medicine, Japan)
- 18:05–18:20 [Short Talk 5 (PS[II]-38)]**
Chimeric antigen receptor T (CAR-T) cell therapy with intrinsic PD-1 blocking for ovarian cancer124
Masayo UKITA
 (Department of Gynecology and Obstetrics,
 Kyoto University Graduate School of Medicine, Japan)
- 18:20–18:35 [Short Talk 6 (PS[II]-52)]**
Blocking tumor-promoting macrophages by interrupting the interaction of chemokine receptors and a cytoplasmic regulatory protein FROUNT138
Etsuko TODA
 (Department of Molecular Preventive Medicine,
 Graduate School of Medicine, The University of Tokyo, Japan)
- 18:35–19:30 Dinner**
- 19:30–20:30 Poster Discussion II (Even Numbers)**
- 20:30–21:30 Poster Session**

FRIDAY, JUNE 29, 2018

9:00–12:20 Session E

Clinical Development of Cancer Immunotherapy

Chairs: Kouji MATSUSHIMA
Antoni RIBAS

9:00–9:40 [E-1]
Overcoming resistance to PD-1 blockade therapy70
Antoni RIBAS
(Division of Hematology-Oncology,
Department of Medicine, University of California,
Los Angeles, USA)

9:40–10:20 [E-2]
**Clonal deletion of tumor-specific T cells by combination checkpoint
blockade compromises anti-tumor efficacy in low tumor burden
states72**
Lawrence H. FONG
(Department of Hematology and Oncology,
University of California, San Francisco, USA/
Helen Diller Family Comprehensive Cancer Center,
University of California, San Francisco, USA)

10:20–10:50 [E-3]
**Adoptive cell therapy with TCR-gene engineered T cells and Beyond
.....74**
Hiroshi SHIKU
(Immuno-Gene Therapy, Mie University
Graduate School of Medicine, Japan)

10:50–11:20 Coffee Break

11:20–11:50 [E-4]
**The activated conformation of integrin $\beta 7$ is a novel multiple
myeloma-specific target for CAR T-cell therapy76**
Naoki HOSEN
(Department of Cancer Stem Cell Biology,
Osaka University Graduate School of Medicine, Japan)

11:50–12:20 [E-5]
Our trials to develop novel combination cancer immunotherapy ...78
Kouji MATSUSHIMA
(Research Institute for Biomedical Sciences,
Tokyo University of Science, Japan)

12:20–12:25 Introduction of The Naito Foundation

12:25–12:30 Announcement of Award Recipients

12:35–12:40 **Closing Remarks:** Yutaka KAWAKAMI

12:40–13:00 **Lunch**